1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 10,40 € (+194,62 %). Medianen er 10,40 € (+194,62 %).
| Køb |
0 |
| Behold |
1 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Zivo Bioscience switches trading to OTCID platform
Zivo Bioscience has transferred its common shares to the OTCID marketplace and has been traded there since Monday. The company, with a market capitalization of $15.21 million, recorded revenue growth of 165% over the past twelve months but remains unprofitable. The stock has fallen 78% year over year and is currently trading at $3.80; existing shareholders keep their holdings. Zivo will continue to provide corporate and financial information via the OTC Markets disclosure page to ensure transparency and market presence. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 0 | 100,00 % |
| Bruttofortjeneste | 0 | 100,00 % |
| Nettoresultat | -449,04 t | 67,73 % |
| EBITDA | -445,98 t | 67,81 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 13,82 mio. € |
Antal aktier | 3,89 mio. |
Højeste/laveste i 52 uger | 15,17 € - 0,96 € |
| Udbytte | Nej |
Beta | 0,11 |
P/E (PE Ratio) | -2,93 |
PEG (PEG Ratio) | -0,05 |
K/I (PB Ratio) | -5,03 |
P/S (PS Ratio) | 242,94 |
Virksomhedsprofil
| Navn | Zivo Bioscience |
| CEO | John Bernard Payne |
| Medarbejdere | 7 |
